

# CONSENSUS STATEMENT: Childhood Obesity

Phyllis W. Speiser, Mary C. J. Rudolf, Henry Anhalt, Cecilia Camacho-Hubner, Francesco Chiarelli, Alon Eliakim, Michael Freemark, Annette Gruters, Eli HersHKovitz, Lorenzo Iughetti, Heiko Krude, Yael Latzer, Robert H. Lustig, Ora Hirsch Pescovitz, Orit Pinhas-Hamiel, Alan D. Rogol, Shlomit Shalitin, Charles Sultan, Daniel Stein, Pnina Vardi, George A. Werther, Zvi Zadik, Nehama Zuckerman-Levin, and Zeev Hochberg, on behalf of the Obesity Consensus Working Group

*Schneider Children's Hospital (P.W.S.), New Hyde Park, New York 11040, and New York University School of Medicine, New York, New York 10016; East Leeds Primary Care Trust (M.C.J.R.), University of Leeds, Leeds LS2 9DE, United Kingdom; St. Barnabas Medical Center (H.A.), Livingston, New Jersey 07039, and State University of New York Downstate Medical School, Brooklyn, New York 11203; William Harvey Research Institute (C.C.-H.), University of London, London EC1A 7BE, United Kingdom; University of Chieti (F.C.), Chieti, Italy 66100; Meir General Hospital (A.E.) and Felsenstein Medical Research Center (P.V.), Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel 69978; Schneider Children's Medical Center, Petah-Tikva 49202, and Sackler Faculty of Medicine (S.S.) and Chaim Sheba Medical Center and Sackler Faculty of Medicine (D.S.), Tel Aviv University, Tel Aviv, Israel 69978; Duke University Medical Center (M.F.), Durham, North Carolina 27710; University Children's Hospital (A.G., H.K.), Charite, Humboldt-University, Berlin, Germany 10099; Soroka University Medical Center (E.H.), Beer-Sheva, Israel 84101; University of Modena and Reggio Emilia A (L.I.), Modena, Italy 41100; Meyer Children's Hospital (Y.L., N.Z.-L., Z.H.), Rambam Medical Center, Haifa, Israel 31096; University of California San Francisco (R.H.L.), San Francisco, California 94143; James Whitcomb Riley Hospital for Children (O.H.P.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Safra Children's Hospital (O.P.-H.), Sheba Medical Center, Tel Hashomer, Israel 52662; University of Virginia (A.D.R.), Charlottesville, Virginia 22911; Hopital Arnaud de Villeneuve (C.S.), Montpellier, France F-34295; Murdoch Children's Research Institute (G.A.W.), University of Melbourne, Royal Children's Hospital, Parkville, Victoria, Australia 3052; and Kaplan Medical Center (Z.Z.), Rehovot, Israel 76100*

**In March 2004 a group of 65 physicians and other health professionals representing nine countries on four continents convened in Israel to discuss the widespread public health crisis in childhood obesity. Their aim was to explore the available evidence and develop a consensus on the way forward.**

**The process was rigorous, although time and resources did not permit the development of formal evidence-based guidelines. In the months before meeting, participants were allocated to seven groups covering prevalence, causes, risks, prevention, diagnosis, treatment, and psychology. Through**

**electronic communication each group selected the key issues for their area, searched the literature, and developed a draft document. Over the 3-d meeting, these papers were debated and finalized by each group before presenting to the full group for further discussion and agreement.**

**In developing a consensus statement, this international group has presented the evidence, developed recommendations, and provided a platform aimed toward future corrective action and ongoing debate in the international community. (*J Clin Endocrinol Metab* 90: 1871–1887, 2005)**

## Prevalence

*What is the scope of the problem?*

There has been a worldwide increase in obesity among people of all ages. The definition of obesity varies but is based on body mass index (BMI) cutoffs described below. As many as 250 million people, or about 7% of the current world population, are obese. Two to three times more people are overweight. In one of the most extreme exam-

ples, the prevalence of overweight doubled among children 6–11 yr of age and tripled among those 12–17 yr of age in the United States between the second National Health and Nutrition Examination Survey, conducted between 1976 and 1980, and the most recent such survey, conducted in 1999 and 2000. Approximately 14–15% of all 15 yr olds in the United States can be classified as obese (1). African-Americans, Hispanics (predominantly Mexican and Puerto Rican), Pima Indians, and other Native Americans have a particularly high predisposition to obesity. There are national differences in prevalence rates for obesity (2). Comparison of cross-sectional data from school-based surveys conducted in 1997 and 1998 describing body size among adolescents in 13 European countries, Israel, and the United States showed that the United States, Ireland, Greece, and Portugal had the highest prevalence of overweight (Table 1) (3). A review of 21 surveys conducted in various European countries indicated a higher prevalence of overweight in western and southern Europe. The countries surrounding the Mediterranean showed prevalence rates for overweight children in the range of

### First Published Online December 14, 2004

Abbreviations: AHI, Apnea-hypopnea index; BBS, Bardet-Biedl syndrome; BIA, bioelectric impedance assay; BMI, body mass index; BWS, Beckwith-Wiedemann syndrome; DEXA, dual-energy x-ray absorptiometry; GDM, gestational diabetes mellitus; HDL, high-density lipoprotein; IOTF, International Obesity Task Force; LDL, low-density lipoprotein; MCR, melanocortin receptor; MS, metabolic syndrome; OGTT, oral glucose tolerance test; OSA, obstructive sleep apnea; POMC, proopiomelanocortin; PWS, Prader-Willi syndrome; RYGB, Roux-en-Y gastric bypass; SES, socioeconomic status; T2DM, type 2 diabetes mellitus.

JCEM is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

**TABLE 1.** Prevalence of BMI  $\geq$ 85th and  $\geq$ 95th percentiles of adolescents 15 yr of age by gender

Country	Boys (%)		Girls (%)	
	$\geq$ 85th	$\geq$ 95th	$\geq$ 85th	$\geq$ 95th
Austria	11.6	5.1	10.9	4.4
Belgium	13.1	5.2	15.4	5.8
Czech Republic	8.1	1.9	9.3	3.5
Denmark	10.4	3.2	18.2	6.5
Finland	15.6	4.9	14.5	5.1
France	9.8	2.7	12.8	4
Germany	14.2	5.4	14.8	5.1
Greece	28.9	10.8	16.4	5.5
Ireland	19.3	2.8	14.2	4.7
Israel	20.1	6.8	16.4	6.2
Lithuania	5.2	0.8	8.1	2.1
Portugal	14.3	5.2	20.8	6.7
Slovakia	16.5	4.4	11.3	1.1
Sweden	12.3	4	12.3	3.4
United States	28.2	13.9	31	15.1
Total	15	5.3	15.3	5.5

20–40%, whereas those in northern areas showed lower rates, in the range of 10–20% (4).

Evaluation of Australian children from surveys taken 10 yr apart also showed an increase of overweight and obesity. By 1995 15% of boys and 15.8% of girls were overweight, and 4.5% of boys and 5.3% of girls were classified as obese (5). In other Asian populations, Polynesians, Micronesians, Anurans, and Maoris are at high risk for obesity.

There has also been a trend toward increasing prevalence of overweight and obesity as well as metabolic complications in developing countries. Regions with the highest prevalence of overweight were: the Middle East, 7%; North Africa, 8%; and Latin America and the Caribbean, 4.5–7% (6).

Overweight children often become overweight adolescents and adults (7), and overweight in adulthood is a serious health risk (8). Obesity is associated with the development of a number of serious medical complications and increased mortality in children and adults. Thus, monitoring trends in the prevalence of obesity in populations worldwide is important for epidemiological assessment.

#### *Why is obesity so prevalent?*

Man has evolved under conditions of stress in which it was advantageous to be able to store fat (9). It is this genetic propensity to store fat in response to insulin, paired with our lifestyles with too much sedentary activity and processed energy-dense foods, that has contributed to the problem of overweight. Numerous genetic markers have been linked with obesity and its metabolic consequences (10), yet identifiable hormonal, syndromic, or molecular genetic abnormalities can presently account for less than 5% of obese individuals (11). This is discussed in greater detail in *Causes*.

### **Diagnosis**

*Clinical evaluation: How do we evaluate overweight and obesity in childhood?*

*Basic evaluation: history and anthropometrics.* The definition of overweight and obesity in childhood is still a matter of debate for two main reasons: the lack of a simple, low-cost,

accurate, and reproducible method to measure fat mass in infants, children, or adolescents and the lack of cutoffs of fat mass for children to identify individuals at moderate or high cardiovascular and metabolic risk in childhood and adulthood. Whitaker *et al.* (12) demonstrated that the prognostic importance of obesity in infancy and childhood depends on the presence or absence of obesity in one or both parents.

It is important to distinguish between primary or idiopathic obesity and the rarer situation of secondary obesity owing to genetic disorders, endocrine disease, central nervous system lesions, or iatrogenic causes. Detailed medical history, physical examination, and laboratory tests are helpful.

In the initial assessment of the overweight or obese child, nutritional history should include breast-feeding or formula; age at introducing solids; and assessment of caloric intake, including dietary quality in terms of the balance of nutrients and food groups. The clinician should ask about the child's level of physical activity; limitations due to weight; and respiratory difficulties including snoring and somnolence, potential signs of sleep apnea.

Physical examination should first be directed to overall body proportions and the presence or absence of any distinctive or dysmorphic features that could guide the diagnosis to rare obesity syndromes. Recording and graphical plotting of height, weight, BMI, and waist circumference should be done at each visit.

*Quantitation of body fat in childhood and adolescence.* Overweight and obesity occur with excessive accumulation of body fat. Because increasing body fat is associated with increasing morbidity, the definition of overweight and obesity should be linked to health risks. Due to difficulties in direct measurement of body fat, obesity can be simply and inexpensively estimated using the BMI. BMI correlates with the amount of body fat in both children and adults (13). The World Health Organization (WHO) classification and U.S. dietary guidelines for obesity in adults define overweight based on health risk as a BMI of 25–30 kg/m<sup>2</sup> and obesity as a BMI of 30 kg/m<sup>2</sup> or greater.

Country-specific growth charts have been developed based on cross-sectional and longitudinal data. For example, the U.S. Centers for Disease Control and Prevention (CDC) 2000 growth charts include gender-specific BMI for age growth charts for ages 2–19 yr (14). These charts were developed from five national data sets in the United States. Overweight and obesity among individuals 2–19 yr old are defined as the 95th percentile or greater of BMI for age; those with BMI between the 85th and 95th percentiles are considered at risk for overweight. In a separate report from the National Heart, Lung, and Blood Institute, overweight is defined in adolescents as the 85th percentile or greater of BMI for age (15). A recent review concluded that the evidence for use of national BMI reference data is sufficiently strong for its adoption in clinical practice and screening (16). An advantage of these charts is that a child can be followed up over time with graphical plotting of serial BMI measures. A disadvantage is that the charts are based on arbitrary statistical measures and not on biological data related to the risk of later morbidity. Moreover, the CDC reference data are based on American children and may not be applicable to other populations. Another problem with this approach is that

as the population becomes heavier, these percentiles define changing thresholds for overweight and obesity.

To have an absolute and internationally relevant definition of child overweight and obesity, Cole *et al.* (2) developed age- and sex-specific cutoff lines from data derived from six countries across several continents using BMI. These charts extrapolate risk from the adult experience to children. The International Obesity Task Force (IOTF) has recommended this approach for the comparison of populations (17). IOTF currently defines overweight as approximately 91% or greater and obesity as approximately 99% or greater. The charts of Cole *et al.* are recommended for epidemiologic purposes and may underestimate the prevalence of obesity if applied to cross-sectional charts. Owing to the lack of precise percentiles, these charts are not useful for longitudinal follow-up of individual patients.

*Quantitation of body fat in infancy.* Weight for length is usually used in the under 2-yr age group. In the United States, overweight in this age group is defined as greater than the 95th percentile of the weight for length. The definition is purely statistical, and the percentile values are age and gender specific. It is important to measure head circumference because a very large head may alter weight-for-length ratio.

#### Laboratory tests for body fat

*What are the most reliable methods of assessment of body fat and its distribution?* As discussed, BMI, an indirect estimate of total adiposity, does not necessarily predict health risk for children. There are some situations in which BMI gives an inaccurate picture, *e.g.* in short muscular people. Furthermore, BMI does not distinguish between sc and visceral fat. It is therefore useful to employ adjunctive measures of total and regional body fat.

*Skinfold thickness.* This is a quick, simple, inexpensive method, which is useful for community pediatrics and large studies and gives information on fat distribution because it is done at several body sites. It does not require a high degree of technical skill, although the technique requires a trained person to standardize the measurements; otherwise it is poorly reproducible, especially at the highest BMIs. Triceps skinfold is correlated with fat mass and, combined with BMI, increases the sensitivity for the determination of percent body fat (18).

*Bioelectric impedance assay (BIA).* BIA is a method of body composition assessment that is simple, quick, relatively inexpensive, and noninvasive. However, BIA measurements are highly variable because they are affected by meals; physical activity; and other variables that change the subject's hydration state, such as menstrual phase, acute illness, kidney disease, and water and electrolyte disturbances (19).

*Hydrodensitometry.* Underwater weighing requires special equipment and is used primarily for research purposes; it is not available for routine clinical care. It is useful for validation of other methods of measuring body fat.

*Dual-energy x-ray absorptiometry (DEXA).* This is a relatively expensive but safe method for assessing total body fat

that has high precision and simplicity for the subject. X-ray exposure is minimal. DEXA also is limited by the inability to distinguish between sc and visceral fat. The method is most useful for research.

*Imaging.* Computed tomography and magnetic resonance imaging of the abdomen are accurate methods that can be used to measure visceral fat (20). However, the disadvantages are high cost and radiation exposure with computed tomography. These methods require more time to perform and specialists for interpretation. Therefore, these methods are also recommended only for research purposes.

*Anthropometrics.* Waist circumference or waist to hip ratios are used as indirect markers of intraabdominal adipose tissue. As with BMI, there is some controversy as to appropriate cutoffs for adults. Waist circumferences above 95 cm indicate elevated mortality rates (21). This parameter is also a predictor of cardiovascular and metabolic risk factors in obese children (22). Visceral or intraabdominal adiposity is also associated with the metabolic syndrome (see definitions in *Risks*) in adults and children. Methodologies such as DEXA, skinfolds, and BIA do not assess visceral fat. Thus, waist circumference should be included in clinical practice as the least invasive and least costly tool to help identify obese children at higher metabolic risk. Currently there are limited pediatric reference values for waist circumference (24, 25), and these should be developed.

#### Causes

*Genetic: which genes are important determinants of obesity?*

*Monogenic obesity.* Leptin was the first specific gene recognized as important in human body weight control. This adipocyte hormone is involved in a complex circuit of hormones and neurotransmitters to control appetite (Table 2). To date, several monogenic obesity syndromes have been identified, and most involve the leptin-melanocortin regulation pathway (26, 27). The known genes include leptin, the leptin receptor proopiomelanocortin (POMC), prohormone convertase 1, melanocortin receptors 3 and 4, and the transcription factor single-minded 1; the list will continue to expand. Severe and early-onset obesity, common findings in monogenic cases, parallels the phenotype in the corresponding knockout mice and supports the central role of these genes in body weight regulation. There have been conflicting reports about the association between obesity and human polymorphisms in genes involved in the regulation of peripheral metabolic control, *e.g.* mitochondrial uncoupling genes, perhaps attributable to ethnic or gender-specific variations (28).

Homozygous mutations of the leptin-melanocortin genes are extremely rare causes of severe obesity and are often associated with other features, *e.g.* hypogonadotropic hypogonadism in leptin deficiency (26) and red hair and hypocortisolism in POMC deficiency (29) resulting in phenotypes that exclude these genes as likely candidates for common obesity. In the case of leptin, leptin receptor, and POMC genes, heterozygous mutation carriers have a minimally abnormal phenotype. Heterozygous mutations causing significant obesity are found only in the melanocortin receptor (MCR) 4 and are not associated with an otherwise distinctive

**TABLE 2.** Factors critical in the regulation of appetite and energy balance

Central nervous system-appetite regulation command: Ventro-medial-hypothalamus, paraventricular nucleus, lateral hypothalamus area		
Appetite stimulation pathway		Appetite suppressing pathway
Agouti-related protein		Cocaine and amphetamine reg. transcript (CART)
GABA		Corticotropin-releasing hormone (CRH)
Galanin		Dopamine
Glutamate		Melanocortin receptors (MC3R, MC4R)
MCH		$\alpha$ -Melanocyte-stim.-hormone (MSH)
Neuropeptide Y		POMC
Norepinephrine		Neurotensin
Opioids ( $\beta$ -endorphin, dynorphin, met-enkephalin)		Serotonin (5-hydroxy-tryptamine)
Orexins, hypocretins		
Peripheral incoming signals		Central nervous system outgoing signals
Suppressing	Stimulating	
Amylin	Cortisol	Parasympathetic nervous system: vagus nerve
Bombesin	Ghrelin	Energy storage by glucose-stimulated insulin secretion
GLP1	Glucose (low)	Sympathetic nervous system: $\alpha$ -adrenergic activation
Glucagon		Stress, cold (lipolysis, heat production, thyroid activation)
Leptin		
Protein		
Insulin		

phenotype. To date, MC4R mutations are the most frequent known cause of monogenic human obesity, occurring in up to 4% of early-onset and severe childhood obesity (30).

*Other candidate genes involved in human obesity.* Because insulin plays a crucial role in energy metabolism, the insulin gene has been examined. There is an association between variable nucleotide tandem repeat polymorphisms upstream of the insulin gene, increased fasting insulin levels, and childhood obesity in individuals of European descent (31).

The human obesity gene map continues to expand as more genes and chromosomal regions are linked with human obesity. In the most recent published update, there were more than 430 genes, markers, and chromosomal regions associated or linked with human obesity phenotypes. There are 35 genomic regions with quantitative trait loci that have been replicated in two or more studies of obesity phenotypes (32). Every chromosome, except the Y chromosome, has had loci linked with the phenotype of obesity. Some genes have been identified that are specific to visceral obesity. Most of the specific genes involved are as yet unknown. In view of these data, it is highly probable that childhood obesity is polygenic with susceptibility conferred via complex genetic factors. It is estimated that 30–50% of the tendency toward excess adiposity can be explained by genetic variations (33).

*Which syndromes are associated with early childhood obesity?*

Obesity is a component of several rare human genetic syndromes that present with characteristic phenotypes; two of these are described here. Prader-Willi syndrome (PWS; OMIM no. 176270) is characterized by intrauterine hypotonia, mental retardation, and hypogonadotropic hypogonadism. The obesity of PWS that occurs in early childhood is resistant to diet and associated with early mortality. PWS is caused by the loss of paternally expressed genes, including small nuclear ribonucleoprotein, within the PWS critical region on chromosome 15q; however, the precise metabolic functions of the missing gene products remain unknown. One major difference in the obesity associated with PWS is

the presence of elevated ghrelin levels contrasting with decreased levels in other forms of obesity. Ghrelin, an orexiogenic protein, may be responsible, at least in part, for the hyperphagia observed in PWS (34).

Bardet-Biedl syndrome (BBS; OMIM no. 209900) is characterized by a variable degree of obesity; mental retardation; and pigmentary retinopathy, polydactyly, and renal abnormalities (35). Based on several large pedigrees with mainly recessive inheritance of the BBS phenotype, several chromosomal regions, including genes involved in cilial and centriole function, have been identified (36).

Beckwith-Wiedemann syndrome (BWS; OMIM no. 130650) is principally characterized as a syndrome of generalized fetal overgrowth and visceromegaly with tall stature but not specifically obesity in childhood.

*Endocrine: are endocrine disorders a common cause of obesity?*

Although rare among children and adolescents with obesity, GH deficiency, thyroid hormone deficiency, and cortisol excess are characterized by a combination of decreased energy expenditure and decreased growth resulting in prominent central adiposity in a short, slowly growing child. GH therapy in individuals with GH or IGF-I deficiency reverses these changes in body composition, reducing fat mass while increasing muscle mass (37). Thyroid hormone replacement increases resting metabolic rate and improves impaired secretion of GH and IGF-I production that accompany thyroid hormone deficiency. Patients with excessive cortisol levels often have hypertension, glucose intolerance, dyslipidemia, moon facies, decreased muscle mass, and broad violaceous striae in addition to visceral obesity and poor growth. Removing the glucocorticoid source ameliorates these problems (38). Insulin and leptin are produced in the periphery, circulate at levels proportional to body fat content, and enter the central nervous system in proportion to their plasma level. Receptors for leptin and insulin are expressed in brain

neurons involved in regulating energy intake; administration of either peptide directly into the brain induces satiety (39). Hyperinsulinism, relative insulin resistance, and to a lesser extent type 2 diabetes mellitus (T2DM) are recognized comorbidities of obesity in the young (40). Insulinomas are rarely diagnosed in children. With hyperinsulinism and normal insulin sensitivity, symptoms of hypoglycemia would herald the diagnosis before the onset of obesity in most cases. Most obese individuals have elevated circulating insulin and leptin levels and are relatively resistant to the satiety-inducing effects of both hormones.

Pseudohypoparathyroidism is a rare cause of childhood obesity, also associated with PTH resistance with hypocalcemia and hyperphosphatemia, short stature, round face, short metacarpals, basal ganglia calcification, and developmental delay.

Laboratory investigations directed at identifying comorbidities of obesity may include thyroid functions, lipid profile, complete chemistries and hepatic profile, and fasting glucose and insulin. An oral glucose tolerance test (OGTT) should be considered to exclude impaired glucose tolerance or T2DM in individuals at high risk, *e.g.* family history of T2DM and/or metabolic syndrome, after 10 yr of age. Determination of serum or urinary cortisol levels should be reserved to exclude the presence of Cushing's syndrome in obese individuals who have appropriate historical information and/or physical findings.

Infants who are hypoglycemic or require very frequent feedings as well as infants with dysmorphic features require further evaluation. Examples include persistent hyperinsulinemic hypoglycemia of infancy (OMIM no. 601820) and BWS with hypoglycemia, or PWS and BBS with dysmorphism.

#### *Neurologic: how can central nervous system lesions cause obesity?*

Obesity is a frequent complication in children surviving serious brain injury, brain tumors, and/or cranial irradiation. Significant increases in weight are noted to occur in the early postoperative period. These children often have reduced physical activity more than increased energy intake. The pattern of decreased physical activity may be secondary to suboptimal hormonal replacement and decreased sympathetic nervous system function. The exact mechanisms responsible for this phenomenon are still unknown, although alterations in hypothalamic neuropeptides (41) and enhanced activity of 11- $\beta$  hydroxysteroid dehydrogenase, converting cortisone to cortisol (42), have been implicated. These individuals often have autonomic dysregulation of the  $\beta$ -cell, with insulin hypersecretion in response to oral glucose tolerance testing (41).

#### *Medications: do medications cause obesity?*

High-dose, chronic glucocorticoid treatment is well known to be associated with a distinctive pattern of centripetal weight gain with visceral fat accumulation predisposing to cardiovascular risk. Other drugs used in children and adolescents that may predispose to weight gain include cyproheptadine, valproate, and progestins.

There is considerable evidence that treatment with some

newer antipsychotic drugs can cause a rapid increase in body weight. There is, however, considerable variability among the various drugs in their effect on weight gain, lipid profile, and risk of diabetes. The prevalence of both diabetes and hyperlipidemia among individuals with schizophrenia and affective disorders is 1.5–2 times higher than the general population (43). Among the second-generation drugs, which have generally replaced first generation, clozapine and olanzapine, have a marked effect on weight gain, with increased risks for developing diabetes and hyperlipidemia. Risperidone and quetiapine have a moderate effect on weight gain and possible effects on development of diabetes and hyperlipidemia. Aripiprazole and ziprasidone are associated with less weight gain and better glucose: insulin and lipid profiles; however, there is less long-term experience with the latter drugs (44).

#### *Environment: how does environment contribute to the genetic predisposition to obesity?*

Genes play a permissive role and interact with environmental factors to promote obesity. Studies of energy balance among pairs of monozygotic twins have shown that subjects with the same genotype are more alike in response to energy surplus and deprivation than are subjects with different genotypes for changes in circulating lipid levels, sc fat, fat mass, and visceral fat in response to dietary changes. Advances in the ability to generate genotypic information, in combination with precise phenotypic markers, will improve our capacity to better determine gene-environment interactions (45).

*Does the in utero milieu contribute to obesity?* Epidemiological studies of the impact of maternal gestational diabetes mellitus (GDM) on adolescent obesity demonstrate conflicting results. Infants of Pima Indians with GDM had an increased risk of obesity, compared with siblings born before their mothers developed GDM. This study supports the role of *in utero* exposure to hyperglycemia as a risk factor for subsequent obesity (36). Other studies (37, 38) demonstrated an increased risk of adolescent overweight associated with increased birth weight and maternal GDM, yet the association was attenuated or lost completely after adjustment for maternal BMI. Thus, the effect of fetal hyperinsulinemia on body composition and size at birth may set the stage for the future development of obesity.

#### *Psychosocial factors*

*What is the impact of socioeconomic status (SES), race, ethnicity, and gender?* Most of the data in this area are derived from the adult population in the United States (46). In general, those with lower income and education levels are more likely to become obese than those with higher income levels and higher education levels, who may have greater awareness of and access to health care, healthy foods, and fitness facilities.

The prevalence of obesity is higher in racial and ethnic minorities, perhaps attributable to greater poverty among these groups. Selective weight gain in certain populations may also indicate that the interaction between people and their environment varies according to genetic background. Clearly some populations are at greater risk of obesity-

related morbidity. Therefore, effective prevention and treatment may require racial and ethnic-specific strategies.

Gender influences the impact of SES and ethnicity on the development of obesity in that a poor woman is twice as likely to become obese as a poor man. Conversely, a wealthy woman is less likely to become obese than a wealthy man. However, a wealthy man is significantly more likely to be overweight than a man with low SES. Overall, women are more likely to be obese than men. In view of the influence of maternal BMI on their children, this is especially concerning. According to the American Obesity Association, among women between the ages of 20 and 74 yr, 34% are obese (BMI  $\geq$  30) and 6.3% are severely obese (BMI  $\geq$  40), compared with 28 and 3.1%, respectively, for men (47).

*What is the role of lifestyle and diet?* Studies using motion sensors have shown that children who spend less time in moderately vigorous activity are at higher risk to become obese during childhood and adolescence (48). In the United States, only about 25% of adolescents report regular exercise, and an alarming 14% say they do not exercise at all. Television and video games have contributed to more sedentary leisure activities as well as increased snacking and inappropriate food choices due to television advertising. There is a positive correlation between hours of television viewing and overweight, especially in older children and adolescents (49).

Aside from these lifestyle issues, eating patterns of children and adolescents have changed dramatically in the past few decades (50). Dietary factors that place children at risk for obesity include high fat and excess calorie intake. Obese children tend to skip breakfast but consume a large amount of food at dinner (51).

In terms of dietary content, there is an inverse relationship between calcium intake and adiposity (52). The consumption of high-carbohydrate soft drinks is a major contributing factor to high calorie counts (53), especially because these fluids tend to replace milk and calcium intake for adolescents. Additionally, fast food consumption now accounts for 10% of food intake in children in U.S. schools, compared with 2% in the 1970s. Children who frequently eat fast food consume more total energy, more energy per gram of food, more total fat, more total carbohydrate, more added sugars, less fiber, less milk (calcium), and fewer fruits and vegetables than children who eat fast food infrequently (50, 54). Those who are overweight are particularly vulnerable to the adverse health effects of consuming fast foods (55).

It appears that neonatal nutrition has an impact on childhood and adolescent obesity. In particular, breast-feeding has been shown to have at least some protective effect in some populations (56, 57), although this has been refuted in other reports (58).

*Is binge eating a major cause of obesity?* Twenty to 40% of severely obese adults (59) and adolescents (60) suffer from binge eating. Obese binge eaters show weight and shape concern as well as symptoms of depression and anxiety with lower self-esteem when compared with nonbingeing obese individuals. Apparently binge eating disorder in youngsters does not develop into bulimia nervosa in later life (61).

*What is the psychological profile of obese children and adolescents?* A causal relationship between obesity and psychological factors remains unclear. Adiposity is very visible, and children tend to rate disease and minor deformities as preferable to obesity at 6 yr of age. Children's perceptions of obesity emphasize laziness, selfishness, lower intelligence, social isolation, poor social functioning, and academic success as well as low levels of perceived health, healthy eating, and activity (62). Thus, children share the overall negative societal perceptions toward those who are overweight or obese. This is regardless of the child's own weight status or gender. Children as young as 5 yr are aware of their own fatness, which impacts their perceptions of appearance, athletic ability, social competence, and self-worth. Quality of life is poor among obese youngsters by parental and self-report (63). Self-esteem in obese children varies with gender and age. Females are at greater risk for self-esteem problems (64). Parental acceptance or lack of concern may be a protective factor for self-esteem.

Among severely obese adolescents, 48% have moderate to severe depressive symptoms and 35% report high levels of anxiety. Obese girls are more likely to have attempted suicide than nonobese girls. Overweight adolescents reported engaging in significantly more unhealthy behaviors and experiencing more psychosocial distress than their nonoverweight peers. Overweight adolescents were found to be more isolated and peripheral to social networks than were their normal-weight peers (65).

## Risks

*Why is obesity of such concern?*

Childhood obesity is now recognized as a major medical and public health problem. Obesity in adults is strongly associated with many serious medical complications that impair quality of life and lead to increased morbidity. Obese children are at high risk for adult obesity, but there are as yet insufficient data to assign specific risk levels in childhood. However, obesity in childhood provides an independent contribution to the development of adult morbidity. Without proper intervention, adult morbidities will likely begin to appear in the young. There are strong epidemiologic and causal links between obesity in the young and earlier-onset T2DM (40).

## Diabetes

Over the past decade, there has been an alarming increase in the appearance of T2DM in children, a disease that formerly occurred almost exclusively in adults. T2DM in youth represents the most rapidly growing form of diabetes in America, Europe, Japan, and Australasia, now responsible for up to about one fifth of new diagnoses of diabetes in pubertal children. Although universal screening is not recommended, the American Academy of Pediatrics and American Diabetes Association recommend that all youngsters who are overweight and have at least two other risk factors should be tested for T2DM beginning at age 10 yr or at the onset of puberty and every 2 yr thereafter (66). The risk factors include family history of T2DM in first- or second-degree relatives; belonging to certain ethnic groups (*i.e.* Na-

tive American, African-American, Hispanic, Japanese, or other Asian/Pacific Islander); or having signs associated with insulin resistance (hypertension, dyslipidemia, acanthosis nigricans, or polycystic ovarian syndrome). Fasting plasma glucose is the primary screen to test for T2DM in young people. The 2-h blood glucose concentration after a standard OGTT is more sensitive than plasma glucose in assessing impaired glucose tolerance in youngsters, but it is also more invasive, inconvenient, and expensive. Insulin resistance is considered the greatest risk factor for the development of T2DM. The homeostatic model assessment, which estimates insulin resistance, and the quantitative insulin-sensitivity check index, based on solely on fasting insulin and glucose, provide a crude, and not always reproducible, measure of indices that are most accurately derived from the more invasive euglycemic and hyperglycemic clamp studies (67).

#### *Metabolic syndrome (MS)*

Metabolic changes seen in obese adults have been summarized under the so-called MS. The MS is defined differently according to different authorities. The U.S. National Cholesterol Education Program's Adult Treatment Panel III (68) requires three of five characteristics: 1) abdominal obesity given as waist circumference greater than 102 cm in men and greater than 88 cm in women; 2) hypertriglyceridemia with triglyceride concentration ( $\geq 150$  mg/dl or 1.7 mmol/liter); 3) abnormal cholesterol profile with high-density lipoprotein (HDL) cholesterol less than 40 mg/dl or 1 mmol/liter in men and less than 50 mg/dl or 1.3 mmol/liter in women; 4) blood pressure: 130/85 mm Hg or more; 5) impaired glucose tolerance, *i.e.* elevated fasting plasma glucose 100 mg/dl or 5.5 mmol/liter or more (69). The National Cholesterol Education Program guidelines for adults have been modified for adolescents such that triglycerides 110 mg/dl or 1.2 mmol/liter or more are considered abnormal, and the HDL threshold is set at 40 or less. Waist circumferences 90% or more (from National Health and Nutrition Examination Surveys III) are considered abnormal, as are blood pressures 90% or more (70). There is as yet no definition of the MS for the pediatric age group, but using adult criteria, the overall prevalence of MS among 12- to 19-yr-olds in the United States was found to be 4.2% (70). Using modified criteria, Weiss *et al.* (71) found that the risk of MS was nearly 50% in severely obese youngsters, and risk increased with every 0.5-U increment in BMI.

The WHO (72) and American Association of Clinical Endocrinologists (73) criteria overlap the above but differ by requiring impaired fasting glucose, impaired glucose tolerance, or frank T2DM as defined on an OGTT. An added diagnostic criterion of urinary albumin excretion rate greater than 20  $\mu$ g/min has been included in the WHO/American Association of Clinical Endocrinologists criteria.

#### *Hyperandrogenism*

In adolescent girls and young women, excess central or abdominal body fat is associated with hyperandrogenemia (74). Sex hormone-producing enzymes are expressed in adipose tissue, and up to 50% of circulating testosterone may

be derived from fat in young women (75). There is also a causal relationship between high androgen activity and hyperinsulinemia in women. To complete the circle, insulin resistance correlates strongly with the abdominal fat in obese adolescent girls. Insulin resistance stimulates ovarian as well as adrenal androgen and estrogen production. Obese females also have lower concentrations of SHBG with consequent further increase in the (free) biologically active fraction of the sex hormones. These hormonal perturbations place the obese adolescent girl at a high risk of menstrual disorders and early onset of polycystic ovarian syndrome. Weight loss induces a decrease in insulin resistance and androgenic activity, particularly in adolescent girls with the abdominal pattern (76).

#### *Cardiovascular factors*

*Heart disease.* Obesity produces a variety of cardiac structural changes and hemodynamic alterations. Excessive adipose accumulation induces increased blood volume and cardiac output. Sleep apnea and obesity-related hypoventilation may contribute to pulmonary arterial hypertension. In morbid obesity these abnormalities may lead to a cardiomyopathy. Studies involving obese children and cardiovascular risk are limited. The Bogalusa Heart Study indicated that increased insulin and glucose levels in heavier children and adolescents might be risk factors for increased left ventricular mass corrected for growth (77). Childhood obesity does predispose to endothelial dysfunction, carotid intimal medial thickening, and the development of early aortic and coronary arterial fatty streaks and fibrous plaques (78). Whether childhood obesity, like adult obesity, increases the risks of myocardial infarction, stroke, and certain malignancies is currently unproved.

*Hypertension.* Hypertension occurs more commonly in obese persons at every age. Childhood obesity is the leading cause of pediatric hypertension. Genetic, metabolic, and hormonal factors such as insulin resistance, increased serum aldosterone levels, salt sensitivity, and possibly elevated leptin levels are linked to the hypertension of obesity. Systolic blood pressure correlates positively with BMI, skinfold thickness, and waist to hip ratio in children and adolescents (79).

#### *Respiratory factors*

*Asthma and other respiratory problems.* The association between asthma and overweight or obesity is debatable. One possible explanation for the apparent association between asthma and obesity is that both asthma and obesity share coincident increased prevalence. In obese people symptoms of breathlessness and wheezing may be due to the increased work of breathing. Alternatively, obesity may have a direct effect on the mechanical behavior of the respiratory system by altering compliance or elastic recoil, resulting in reduced effective lung volume, airway caliber, or respiratory muscle strength (80).

*Sleep disorders.* There is a strong association between obesity and obstructive sleep apnea (OSA) according to several cohort studies (81). Obese children are 4–6 times more likely to have OSA, compared with lean subjects (82). OSA is di-

agnosed by an overnight sleep study to measure the apnea-hypopnea index (AHI). An AHI of 5/h or more establishes the diagnosis of OSA. Weight reduction is the preferred modality to minimize AHI. OSA in adults has been related to the development of hypertension, cardiovascular diseases, behavioral disorders, and poor quality of life (83).

#### *Visceral factors*

**Nonalcoholic fatty liver disease.** Obesity is associated with a spectrum of liver abnormalities, referred to as nonalcoholic fatty liver disease. Characteristic biochemical findings include 4- to 5-fold elevations in hepatic transaminases, and 2- to 3-fold elevations in alkaline phosphatase and  $\gamma$  glutamyl transpeptidase. Bilirubin, albumin, and prothrombin may rise in later stages. The natural history varies according to histology: hepatic steatosis is frequently characterized by a benign clinical course without histological progression; however, nonalcoholic steatohepatitis may become associated with increasing fibrosis and eventual rare cirrhosis (84).

Most children and adults are relatively asymptomatic. Some individuals may have right upper quadrant pain, abdominal discomfort, weakness, fatigue, or malaise. Hepatomegaly and stigmata of liver disease, such as palmar erythema, vascular spiders, muscle wasting, jaundice, and hepatic encephalopathy, may sometimes be present.

**Gallbladder disease.** Obesity, MS, and hyperinsulinemia, or alternatively rapid and significant weight loss are important risk factors for gallstone development (85). The mechanisms involved are not entirely clear. Early recognition of the severity of gall bladder disease is necessary for successful management. Thus, gall bladder disease should be considered in the differential diagnosis of persistent abdominal pain in obese adolescents.

#### *Orthopedic factors*

Overweight children are susceptible to developing bony deformities that can predispose them to other orthopedic problems later in life. Excess weight may cause injury to the growth plate and result in slipped capital femoral epiphysis, genu valgum, tibia vara (Blount's disease), flat kneecap pressure/pain, flat foot, spondylolisthesis (low back pain), scoliosis, and osteoarthritis (86).

#### *Dermatologic factors*

Acanthosis nigricans, frequently found in young obese individuals, is characterized by hyperpigmented, hyperkeratotic, velvety plaques on the dorsal surface of the neck, in the axillae, in body folds, and over joints. Severe skin changes correlate with elevated serum insulin levels and can be ameliorated by weight loss and consequent reduction in insulin resistance. Other skin problems commonly encountered include skin tags and keratosis pilaris (87).

#### *Neurologic factors*

Obesity is associated with idiopathic intracranial hypertension, or pseudotumor cerebri, manifested by headache, vision abnormalities, tinnitus, and sixth nerve paresis. Al-

though the prevalence of intracranial hypertension increases up to 15-fold with increasing BMI, the risk of intracranial hypertension is increased even in persons who are only 10% above ideal body weight (88).

### **Prevention**

*Perinatal life: is there a need for preventive strategies in infancy or even prenatally?*

**Birth weight, postnatal weight gain, and subsequent obesity.** Human and animal data link the intrauterine environment to postnatal health, with the underlying mechanisms still unknown. A U-shaped relationship exists between birth weight and obesity in young adult life. Low birth weight owing to maternal undernutrition, smoking, or placental insufficiency, or alternatively large size at birth attributable most often to GDM, may both be associated with obesity (89, 90). Furthermore, the timing of prenatal nutritional deprivation is apparently important in the future development of obesity, as discerned in the study of Dutch men exposed to wartime famine (91). Obesity and ensuing metabolic complications often persist into middle age. Restricted prenatal growth with rapid postnatal growth may be key to the early pathogenesis of adulthood disease. It is likely that genetic factors in combination with intrauterine programming influence outcomes (92). As discussed above, breast-feeding is not unconditionally protective for future obesity, although there are numerous other benefits.

Proposed suggestions for preventing childhood obesity beginning in prenatal life and throughout the life cycle at all levels of society are shown in Table 3.

#### *School-age population*

*How can we promote a healthy eating environment for children?* Public health strategies to prevent obesity should begin with schools and extend to the entire community (93). Schools must review their policies and procedures to promote healthy eating. This should include review of vending machine offerings, food available in school cafeterias, and types of food allowed for classroom events. A curriculum for nutrition education to promote healthy eating habits, healthy body image, and weight management is essential from preschool through high school. Healthy eating opportunities include affordable, palatable fresh fruits and vegetables and lower-fat food choices in school cafeterias and vending machines (94, 95). Regulatory agencies should ban advertising of fast foods directed at preschool children and restrict advertising to school-age children.

*How can we encourage physical activity?* Lack of physical activity is not limited to inner-city populations but cuts across socioeconomic, gender, and racial lines (96). A first step toward increasing activity is to restrict sedentary activities. Another crucial element for children is to make exercise readily accessible at all ages in schools and residential areas. Age-appropriate exercises should be fun, not punitive. Schools should mandate minimum standards for physical education, including 30–45 min of strenuous exercise two to three times weekly.

**TABLE 3.** Proposed suggestions for the prevention of obesity

- 
- A. Pregnancy
1. Normalize BMI prior to pregnancy.
  2. Do not smoke.
  3. Maintain moderate exercise as tolerated.
  4. In gestational diabetics, meticulous glucose control.
- B. Postpartum and infancy
1. Breast-feeding is preferred for a minimum of 3 months.
  2. Postpone introduction of solid foods and sweet liquids.
- C. Families
1. Eat meals as a family in a fixed place and time.
  2. Do not skip meals, especially breakfast.
  3. No TV during meals.
  4. Use small plates and keep serving dishes away from the table.
  5. Avoid unnecessary sweet or fatty foods and soft drinks.
  6. Remove televisions from children's bedrooms; restrict times for TV viewing and video games.
- D. Schools
1. Eliminate fundraisers with candy and cookie sales.
  2. Review contents of vending machines for healthier choices.
  3. Install water fountains.
  4. Educate teachers, especially physical education and science faculty, about basic nutrition and benefits of physical activity.
  5. Educate children from preschool through high school on appropriate diet and lifestyle.
  6. Mandate minimum standards for physical education, including 30–45 min of strenuous exercise two to three times weekly.
  7. Encourage “the walking schoolbus.”
- E. Communities
1. Increase family-friendly exercise/play facilities for all age children.
  2. Discourage the use of elevators and moving walkways.
  3. Provide information on how to shop and prepare healthier versions of cultural-specific foods.
- F. Healthcare providers
1. Explain biological and genetic noncontrollable contributions to obesity.
  2. Give age-appropriate expectations for body weight in children.
  3. Work toward classifying obesity as a disease to promote recognition, reimbursement for care, and willingness and ability to provide treatment.
- G. Industry
1. Mandate age-appropriate nutrition labeling for products aimed at children (e.g., red-light/green-light foods, with portion sizes).
  2. Encourage marketing of interactive video games in which children must exercise in order to play.
  3. Use celebrity advertising directed at children for healthful foods to promote breakfast and regular meals.
- H. Government and regulatory agencies
1. Classify obesity as a legitimate disease.
  2. Find novel ways to fund healthy lifestyle programs, *i.e.* with revenues from food/drink taxes.
  3. Subsidize government-sponsored programs to promote consumption of fresh fruits and vegetables.
  4. Provide financial incentives to industry to develop more healthful products and to educate the consumer on product content.
  5. Provide financial incentives to schools that initiate innovative physical activity and nutrition programs.
  6. Allow tax deductions for the cost of weight loss and exercise programs.
  7. Provide urban planners with funding to establish bicycle, jogging, and walking paths.
  8. Ban advertising of fast foods directed at preschool children, and restrict advertising to school-age children.
- 

## Screening

*Are screening programs indicated?* The justification of any screening program is to improve important health outcomes with benefits that will outweigh inconvenience and cost and direct risks to the subjects. Screening programs for obesity and its complications would be justified if earlier intervention were shown to reduce morbidity and mortality. Several systematic reviews have examined the evidence regarding the benefits, limitations, and cost-effectiveness of a broad range of clinical preventive services for obesity (97). None of the published trials has evaluated mass screening, but surrogate measures, *i.e.* preventive strategies, have been examined. Firm evidence for the long-term effectiveness of any single preventive strategy in children is lacking (98). Nonetheless, in the opinion of this group, primary care physicians should screen all children for overweight and obesity. Ideally, where resources permit, children with BMI indicative of overweight status (*i.e.* >85th percentile by the U.S. CDC graphs or >~91% by the European-Cole graphs) should receive weight management counseling, and those with obesity, *i.e.* BMI at or above the 95th or 99th percentile in the respective population graphs, should be screened for comorbidities discussed above under *Causes and Risks* and referred to appropriate specialists if these problems are detected.

## Treatment

### General considerations

*What is the rationale for early intervention?* Obese children and adolescents, like obese adults, are prone to develop many of the comorbidities outlined above; they also suffer emotional distress. The vulnerability of the obese child to serious complications makes the case for prevention and treatment irrefutable. Still there are some obese children and adults who appear to suffer few or no metabolic complications (99); the factors that differentiate such subjects from other obese patients are currently unknown, and this is a fertile area for future research.

*At what point does excess weight gain justify intervention?* Recent studies of American children and adolescents demonstrate that fasting serum glucose, insulin, triglycerides, C-reactive protein, and IL-6 concentrations and the prevalence of impaired glucose tolerance and systolic hypertension increase significantly with increasing obesity (BMI z score  $\geq 2$ ), whereas HDL-cholesterol and adiponectin levels decline (71). Even overweight children (BMI 85–95th percentile) are at increased risk for dyslipidemia and insulin resistance. In contrast, rates of dyslipidemia, hypertension, and glucose intolerance are low among children with BMI less than the 85th percentile for age. Thus, modified diets with decreased sedentary activities can be justified for children with BMI between the 85th and 95th percentiles, and more aggressive treatment should be directed toward children and adolescents with BMI at or above the 95th percentile (or z score  $\geq 2$ ) or in less obese children who suffer metabolic, orthopedic, or cardiopulmonary complications and/or psychological distress.

*At what age should treatment begin?* Most of the metabolic complications of childhood obesity emerge in adolescence

and young adulthood. However, five lines of evidence reviewed above suggest that intervention is warranted, even in obese children. First, severe obesity in toddlers and young children is frequently accompanied by sleep apnea (82) and orthopedic anomalies (Blount's disease) (86). Second, some obese children develop glucose intolerance, T2DM, dyslipidemia, and hypertension even before the onset of puberty (71). Third, excessive weight gain between the ages of 2 and 10 yr increases the risks of adult obesity and glucose intolerance, especially when the parents are obese and/or have diabetes (12). Fourth, early vascular lesions have been detected in obese children as young as 3–8 yr of age, suggesting strongly that obesity-related atherogenesis begins in childhood (78). Finally, intervention to prevent or reverse obesity in its early stages perhaps may be more successful and beneficial than treatment of established, severe obesity in adolescence or adulthood.

*What are the goals of treatment?* Goal setting and treatment of pediatric patients, many of whom are still growing, must be individualized. The first goal is to restore the balance between energy intake and energy expenditure; in cases in which intake is clearly excessive, it will be necessary to restrict calories while increasing energy expenditure.

Stabilization of weight in growing children decreases BMI z score slowly. Nevertheless, studies in adults suggest that a 5–10% reduction in body weight at a rate of 0.5 kg/wk and maintained over a period of 2–5 yr may increase insulin sensitivity and improve glucose tolerance (100) among other salutary changes. Thus, obese children (and their physicians) should be encouraged by any reduction in BMI z score. The long-term objectives of treatment of childhood obesity are to reduce BMI z score to less than 2 and reverse and prevent short- and long-term comorbidities.

### Lifestyle

*Which treatment approach should be used first?*

*General considerations.* The benefits of lifestyle intervention are most likely to be achieved when diet and exercise programs are coordinated with individual and family counseling and behavior modification (101). Long-term success requires continuous implementation; experience in adults indicates that discontinuation of any therapeutic approach leads to rebound weight gain in the great majority of subjects. Eating disorders and other psychiatric disorders are common in obese subjects and must be addressed; otherwise, therapeutic failure is assured.

Parents provide a child's contextual environment and thus should be considered key players in interventions aimed at preventing or treating weight-related problems. Parenting style and feeding style are crucial factors in fostering healthy lifestyle and awareness of internal hunger and satiety cues and deemphasizing thinness (102). In most family-based behavioral weight-loss programs for children, the obese child is the main target of change with varying degrees of parental involvement (103). Interestingly, recent reports suggest greater weight loss in obese children when parents alone are targeted for intervention (104). These data suggest that the

stigma of obesity treatment *per se* may be counterproductive in this age group.

*Dietary approaches.* Mild caloric restriction is safe and can be effective when obese children and their families are motivated and encouraged to change longstanding feeding behaviors. An example of such a program aimed at families with children is the traffic light diet (105). Significant reductions in weight are unusual and often transient unless caloric restriction is accompanied by increased energy expenditure. Diets severely restricted in calories, including high-protein, very low-calorie diets, can facilitate more dramatic short-term weight loss. However, such diets cannot be sustained under free-living conditions (106) and are potentially dangerous. Severe caloric restriction may cause deficiencies of vitamins, minerals, and critical micronutrients; limit bone accretion and mineralization; reduce rates of linear growth; and disrupt menstrual cycles (107).

The role of specific dietary macronutrients in the pathogenesis and treatment of obesity is highly controversial. A low-fat diet in combination with exercise and weight loss can reduce significantly the risks of T2DM and cardiovascular disease in adults with impaired glucose tolerance. Yet recent investigations showed that obese men and women lost more weight and had more significant reductions in plasma triglyceride concentrations on low-carbohydrate diets than on conventional low-fat diets (108). A 3-month study in overweight adolescents found similar effects (mean decrease in weight 9.9 kg in the low-carbohydrate group *vs.* 4.9 kg in the low-fat group); low-density lipoprotein (LDL) levels declined with the low-fat diet but not with the low-carbohydrate diet (109). A review of adult studies suggests that the efficacy of low-carbohydrate diets may be related to overall caloric restriction rather than reduction in carbohydrate intake *per se*. Moreover, the benefits of low-carbohydrate diets may diminish with time (110).

Limited evidence suggests that the nature or quality of ingested carbohydrate may modulate childhood weight gain. The insulin secretory response to foods containing rapidly absorbed, concentrated carbohydrates (high glycemic index) exceeds the response to foods containing high concentrations of protein, fat, and fiber. Studies of the effects of glycemic index on weight gain in children are inconclusive. Still, observations among adolescents have found that consumption of sugar-sweetened drinks is an independent variable associated with increasing BMI (53, 111). In a separate study, a modified low-glycemic diet (45–50% carbohydrate, 30–35% fat) reduced BMI (–1.3 *vs.* 0.7 with a low-fat diet) and fat mass in obese adolescents (112). Thus, it appears that elimination of carbonated drinks or other sugary drinks (juice and sports drinks) from the diet can significantly reduce caloric intake and obesity (113).

Other macronutrients, vitamins, and trace elements may modulate the risk of metabolic complications. For example, intake of fiber (particularly whole grains and cereal) correlates inversely with the risks of T2DM and cardiovascular disease (114). Insoluble and soluble fibers limit macronutrient absorption and thereby increase fat oxidation and improve glucose tolerance. The intake of magnesium (from whole grains, nuts, and green leafy vegetables) and dairy

products containing vitamin D and calcium may also correlate inversely with the risks of obesity and T2DM in children and young adults (115).

**Exercise.** A sedentary lifestyle increases the risks of childhood obesity and predisposes to diabetes and cardiovascular disease, whereas exercise, in combination with caloric and fat restriction, reduces the rate of progression to diabetes in adults with impaired glucose tolerance and limits cardiovascular morbidity and mortality. The benefits of exercise are mediated, at least in part, by reductions in total and visceral fat stores and increases in lean body mass, which augment resting energy expenditure (116). Exercise enhances adipose tissue sensitivity to insulin; reduces fasting and postprandial free fatty acid, LDL, and triglyceride concentrations; and increases plasma HDL levels. The heightened sensitivity to insulin and induction of fatty acid oxidation enhance vascular endothelial function (117).

Available evidence, albeit limited, suggests that exercise can benefit obese children and reduce the risks of metabolic and cardiovascular complications. A randomized, modified cross-over study of 79 obese children (aged 7–11 yr) demonstrated that 4 months of exercise training (40 min of activity 5 d/wk) reduced percent body fat (5%) and decreased fasting insulin (10%) and triglyceride (17%) concentrations, even in the absence of dietary intervention (118). Additional uncontrolled trials suggest that aerobic exercise can also improve vascular endothelial function (119). The benefits of exercise are quenched or reversed rapidly if activity is not maintained.

The capacity for voluntary exercise declines as BMI rises. It is therefore critical to begin regular exercise before the child becomes morbidly obese and functionally immobile. A summary of proposed suggestions for basic lifestyle intervention in children is provided in Table 4. The Cochrane study concluded that “there are limited high-quality data on the effectiveness of obesity prevention programs, and no generalizable conclusions can be drawn. However, concentration on strategies that encourage reduction in sedentary behaviors and increase in physical activity may be fruitful” (98). Thus, lack of formal evidence does not preclude action.

Diet and exercise regimens may prove effective for short-term treatment of pediatric obesity. However, the long-term

success of lifestyle intervention alone has been disappointing. For example, in an Italian multicenter study of nutritional intervention in 1383 obese pediatric patients, drop-out rates ranged from 30–34% after 3 months to 90–94% after 2 yr (120). Noncompliance was highest in the most obese children. A Cochrane review of randomized, controlled trials of duration 6 months or more (n = 18 studies, 975 participants) concluded that most studies are too small to detect effects of treatment, and few trials use the same comparisons and outcomes (103). Thus, the data are of limited quality.

#### Pharmacotherapy

If supervised lifestyle intervention fails, the patient should be referred to a subspecialist for evaluation. The subspecialist should assess the extent and magnitude of comorbidities and may consider more intensive therapeutic approaches including pharmacotherapy. Current pharmacologic interventions are designed to increase energy expenditure (stimulants), suppress caloric intake (anorectic agents), limit nutrient absorption and/or modulate insulin production and/or action.

**Stimulants.** The use of metabolic stimulants for the treatment of obesity has a checkered history. Many antiobesity drugs once considered safe and effective, *i.e.* thyroid hormone, dinitrophenol, amphetamine, fenfluramine, dexfenfluramine, phenylpropanolamine, and ephedra, have been abandoned because they caused dangerous and in some cases life-threatening complications.

A single short-term trial compared caffeine plus ephedrine with placebo in adolescents taking a mildly hypocaloric diet. Although the drug-treated subjects lost more weight, adverse effects were more frequent (121). These agents cannot be recommended.

**Anorectic agents.** The only anorectic agent currently approved for use in obese adolescents (older than 16 yr) is sibutramine, a nonselective inhibitor of neuronal reuptake of serotonin, norepinephrine, and dopamine. In combination with caloric restriction and a comprehensive family-based behavioral program, sibutramine reduced BMI  $8.5 \pm 6.8\%$  in 43 obese adolescents during an initial 6-month period; a  $4.0 \pm 5.4\%$  reduction in BMI was achieved in 39 placebo-treated subjects (122). No additional weight loss occurred during a subsequent 6 months of therapy. Fasting insulin concentrations declined and HDL levels increased. However, 19 of 43 subjects treated with sibutramine developed mild hypertension and tachycardia, necessitating reduction in drug dose, and five had sustained elevations in blood pressure that required discontinuation of the drug. Other potentially serious complications include insomnia, anxiety, headache, and depression. There is a heightened risk of the serotonin syndrome if sibutramine is used in combination with monoamine oxidase inhibitors, buspirone, lithium, or meperidine, or selective serotonin reuptake inhibitors, such as fluoxetine, triptans, dextromethorphan, ergot alkaloids, or fentanyl.

Anorectic agents should complement, never replace, a diet and exercise program. The drugs have modest effects on total body weight (typically an additional 2–10 kg in obese adults), and responses vary considerably among individuals. Most of the weight loss from anorectic agents is achieved within the

**TABLE 4.** Basic treatment interventions: lifestyle changes

Dietary suggestions	
1.	Eliminate all sugary drinks (including juice), and replace with water, noncaloric beverages, and lowfat or skim milk.
2.	Restrict calories enough to produce mild negative energy balance.
3.	Reduce intake of saturated fats, salty snacks, and high glycemic foods including candy, white bread, white rice, pasta, and potatoes.
4.	Create a balanced diet containing vegetables, fruits, whole grains, nuts, fiber, lean meat, fish and low-fat dairy products.
Exercise suggestions	
1.	Exercise should be fun, age-specific, and tailored to the child's fitness level and ability.
2.	Involve large muscle groups to increase energy expenditure.
3.	Increase frequency, intensity, and duration with time.
4.	Restrict sedentary behaviors: television viewing, video games, and internet “surfing.”

first 4–6 months of treatment due to the achievement of a negative plateau; regain of weight is the norm unless drug therapy is maintained. Administration of this drug is not recommended for more than 2 yr duration.

Leptin treatment has been given to children with genetic leptin deficiency resulting in dramatic weight reduction (26), but it is doubtful that individuals with nonleptin-deficient forms of obesity will benefit from similar treatment.

*Drugs that limit nutrient absorption.* The drug orlistat inhibits pancreatic lipase and thereby increases fecal losses of triglyceride. Orlistat decreases body weight and total and LDL cholesterol levels and reduces the risk of T2DM in adults with impaired glucose tolerance. In the United States, orlistat is currently approved by the Food and Drug Administration in children older than 12 yr. In obese adolescents, the combination of orlistat with lifestyle intervention reduced weight ( $-4.4 \pm 4.6$  kg), BMI ( $-1.9 \pm 2.5$  kg/m<sup>2</sup>), total cholesterol ( $-21.3 \pm 24.7$  mg/dl or  $0.55 \pm 0.64$  mmol/liter), LDL ( $-17.3 \pm 15.8$  mg/dl or  $0.45 \pm 0.41$  mmol/liter), fasting insulin ( $-13.7 \pm 19.0$   $\mu$ U/ml or  $95.1 \pm 132.0$  pmol/liter), and fasting glucose ( $-15.4 \pm 7.4$  mg/dl or  $0.85 \pm 0.41$  mmol/liter) concentrations and increased insulin sensitivity during a 3-month trial period (123). There was considerable variability in response to the drug. Variable reductions in body weight ( $-12.7 \pm 2.5$  kg) and fat mass were also noted in a study of 11 morbidly obese children aged 7–12 yr. Side effects are tolerable as long as subjects reduce fat intake, but vitamin A, D, and E levels may decline despite multivitamin supplementation. High study dropout rates (25% or more) suggest that long-term fat restriction is problematic in teenagers; dietary noncompliance results in flatulence and diarrhea that ultimately prove unacceptable.

*Insulin sensitizers and suppressors.* The synthesis and storage of triglyceride in adipose tissue are stimulated by insulin. Thus, increases in nutrient-dependent insulin production and/or fasting hyperinsulinemia may contribute to fat storage and limit fat mobilization. By reducing fasting or postprandial insulin concentrations, certain pharmacologic agents may prove beneficial in the treatment of obese children and adults. In this drug class, only metformin treatment results in weight loss.

*Metformin.* Metformin is a bisubstituted, short-chain hydrophilic guanidine derivative that activates AMP protein kinase. Its major site of action is the liver: the drug increases hepatic glucose uptake, decreases gluconeogenesis, and reduces hepatic glucose production. Major advantages of the drug include decreased food intake, weight loss, decreased fat stores (sc more than visceral), improved lipid profiles, and a reduction in conversion to T2DM among adults with impaired glucose tolerance.

There have been two randomized, double-blind, placebo-controlled studies of metformin in obese adolescents with insulin resistance, normal glucose tolerance, and a positive family history of type 2 diabetes. In the first trial ( $n = 29$ ), metformin reduced BMI z score (3.6% relative to placebo controls), plasma leptin, and fasting glucose ( $-9.8$  mg/dl or  $0.54$  mmol/liter) and insulin ( $-12$   $\mu$ U/ml or  $83.3$  pmol/liter), even in the absence of dietary intervention (124). In the

second trial ( $n = 24$ ), in conjunction with a low-calorie diet, metformin reduced weight 2.7% relative to controls and decreased plasma leptin, insulin, glucose, cholesterol, and triglyceride concentrations (125).

Metformin is generally well tolerated, although many patients have transient abdominal discomfort, avoidable by taking the medication with food. Lactic acidosis is extraordinarily rare in pediatric patients, but metformin should not be administered to children with underlying cardiac, hepatic, renal, or gastrointestinal disease. Obese subjects with mild elevations in hepatic enzymes (less than 3-fold higher than established norms) may receive the drug; indeed, some studies suggest that metformin may be useful in treatment of hepatic steatosis. Concurrent use of a multivitamin is warranted because metformin increases urinary excretion of vitamins B<sub>1</sub> and B<sub>6</sub>. Metformin is approved by the Food and Drug Administration for treatment of T2DM but not currently for treatment of childhood obesity or insulin resistance.

*Octreotide.* Octreotide binds to the somatostatin-5 receptor and thereby impairs closure of the  $\beta$ -cell calcium channel, reducing glucose-dependent insulin secretion. In a double-blind, placebo-controlled trial in children with hypothalamic obesity, octreotide reduced insulin secretory responses and rates of weight gain ( $+1.6 \pm 0.6$  vs.  $+9.2 \pm 1.5$  kg) and BMI ( $-0.2 \pm 0.2$  vs.  $+2.3 \pm 0.5$  kg/m<sup>2</sup>) (126). The cost of the medication, the need for parenteral administration, and the drug's side effects, which may include transient gastrointestinal distress, gallstones, suppression of GH and TSH secretion, and cardiac dysfunction, limit its current applicability to patients with intractable obesity from hypothalamic injury.

#### *Bariatric surgery*

The long-term success of lifestyle intervention and pharmacotherapy in subjects with severe obesity has in general been disappointing. Marked weight loss is highly unusual and rarely sustained, and metabolic and vascular complications are common, albeit not universal. More aggressive approaches such as bariatric surgery may be indicated in selected subjects with extreme obesity and serious comorbidities. The surgical approaches now used most commonly are the laparoscopic gastric banding procedure and the Roux-en-Y gastric bypass (RYGB).

Gastric banding may cause esophageal dilatation and achalasia and may exacerbate gastroesophageal reflux. Other potential complications include port site malposition or malfunction, balloon rupture, and infection. Complications of RYGB include iron-deficiency anemia (50%); folate, thiamine, or calcium deficiencies (at least 30%); cholecystitis (20%); wound infections and dehiscence (10%); small bowel or stomach obstruction (5–10%); atelectasis and pneumonia (12%); and incisional hernia (10%). Prophylactic tracheostomy may be required to maintain airway patency and correct preoperative hypercapnia. Other possible complications include leaks at the anastomotic junction, gastric dilatation, and dumping syndrome. Among the most serious complications are potentially fatal pulmonary emboli. Mortality rates for RYGB range from 1 to 5%. Complication rates may be reduced if bariatric procedures are performed through laparoscopy by an experienced surgeon. There have been

relatively few published surgical trials pertaining to adolescents (127, 128); however, the outcomes seem to parallel bariatric surgery performed in adults (129) and warrant further investigation (130).

#### Care coordination

*How should the clinician balance lifestyle intervention, pharmacotherapy, and surgery in the treatment of obesity?* Lifestyle intervention is indicated for all overweight and obese children and should be maintained, even if more aggressive/intensive measures are adopted.

Pharmacotherapy may be considered for complicated obesity in peripubertal children or adolescents who fail to respond to at least a 6-month trial of supervised lifestyle intervention despite good faith effort. The term complicated obesity implies the presence of major comorbidities including glucose intolerance, hypertension, dyslipidemia, sleep apnea, or other comorbidities discussed above. Failure to respond means that the comorbidities persist or worsen despite lifestyle intervention. Good faith effort means the patient has attempted to follow dietary recommendations and has increased energy expenditure through regular exercise.

Given its efficacy in treating obese, insulin-resistant adolescents, its track record of safety, and its ability to limit food intake and weight gain, the authors consider metformin the drug of choice for treating the obese adolescent with severe insulin resistance or glucose intolerance.

Anorectic agents such as sibutramine should not be administered to prepubertal children. Use of this drug in anyone under age 16 yr remains experimental and should be undertaken only in specialized pediatric treatment centers in the context of clinical trials approved by institutional review boards. Neuropsychologic testing before and during therapy may be warranted. Inhibitors of nutrient absorption such as orlistat are not tolerated by many obese children but might be applied successfully in selected, highly motivated patients. The use of octreotide for treatment of hypothalamic obesity, although promising, remains experimental. Other medications are in phase III studies in obese adults (reviewed in Ref. 131) but will not be available for children for several years.

Firm or uniform guidelines regarding duration of pharmacologic treatment are not feasible at this time. A trial off medication may be warranted if comorbidities are reversed, particularly if there has been a significant decline in BMI z score. In all cases, pharmacotherapy should be discontinued if the patient fails to respond to the drug.

Bariatric surgery should be reserved for treatment of adolescents with extreme obesity (usually defined as BMI > 40 or > 35 with established comorbidities) who have failed other treatment approaches. Surgery should be performed only under the rubric of clinical trials in medical centers that have expertise in bariatric surgical techniques and are supported by multidisciplinary teams with long-standing experience in the evaluation and management of obese children. Contraindications to bariatric surgery include substance abuse or psychiatric disabilities (including severe eating disorders) that prevent lifelong compliance with nutritional recommendations or medical surveillance (127, 128).

*Who should receive intensive evaluation and treatment?* In most cases, the primary care physician will be responsible for management of overweight infants and children. Clearly the burden is too large to be borne by specialty physicians. It is very important for primary care physicians to recognize individual overweight patients and intervene before they become obese (132). Basic dietary advice should be provided in the primary care setting. This should include elimination of all sweetened beverages, including juices, caloric carbonated drinks, iced tea, and lemonade; use of low-fat or fat-free milk in children over the age of 2 yr; portion control; increased fruit and vegetable intake; reduction in fast food consumption; and counseling about the need for daily vigorous exercise. Weekly office weigh-ins can monitor home progress, and if this is deemed insufficient, the child should be seen by a registered dietitian or enrolled in a formal weight-management program. Patients who have unusual distinguishing characteristics may require a specialist's consultation.

There are several examples of these characteristics. First, infants who have rapid weight gain and abnormally low linear growth are likely to have an underlying disease. In addition, infants with syndromic features, neurological deficits, or abnormal fat distribution associated with obesity require further expert evaluation.

In addition, children and adolescents who meet the criteria for obesity (BMI > 95%) and those with eating disorders should be referred for expert evaluation and intervention. Children with an early age of adiposity rebound (the period when the BMI begins to increase after reaching a nadir in early childhood) are at highest risk for overweight, later glucose intolerance, and diabetes (133). These children also need a thorough clinical evaluation.

As genotype-phenotype knowledge increases, lifestyle, pharmacologic, and surgical therapies may be applied more rationally to specific individuals.

*Where should delivery of advanced care be centered?* Obese patients with comorbidities such as sleep apnea, glucose intolerance, hypertension, nonalcoholic steatohepatitis, polycystic ovarian syndrome, and dyslipidemia will require the expertise of subspecialists in pediatric endocrinology, gastroenterology, nutrition, cardiology, exercise and sports medicine, pulmonary medicine, orthopedics, and behavioral medicine; their efforts must be coordinated within the setting of specialized obesity clinics. Until a safe and effective treatment can be recommended for severely obese children, intensive inpatient treatment approaches should remain an option in specialized centers for limited durations in the context of a comprehensive, long-term management program. The intensive therapies that have been used to treat pediatric and adolescent obesity include very low-calorie diets, pharmacotherapy, and bariatric surgery. Psychosomatic units specializing in the treatment of eating disorders are the logical choice by providing a milieu for the obese children and adolescents with life-threatening medical complications. Such programs adhere to recommendations of the Expert Committee on Obesity Evaluation and Treatment for an effective behavioral and nutritional approach for child obesity (134). These include a group format with individualized behavioral counseling, intensive family involvement and training, behavior modification targeted at changing home and family

**TABLE 5.** Summary of proposals

Definitions	Clinical overweight: BMI at or above 85th centile Clinical obesity: BMI > 95th centile on national charts (99th centile on UK charts) Epidemiological or international studies: IOTF cutoffs
Preventive strategies	Action is required antenatally, in schools, community facilities, marketing, government and regulatory agencies.
Screening Assessment	Population screening is required to identify overweight children with BMI > 85th centile Laboratory assessment of children above 95th centile should include: a) Thyroid and liver function tests, fasting glucose, insulin and lipid profile. b) Children at increased risk for the metabolic syndrome require periodic oral glucose tolerance tests from age 10. c) Screening for other comorbidities: <i>e.g.</i> , hypertension, sleep apnea, orthopedic problems, <i>etc.</i>
Treatment	Children with BMI at or above 85th centile should receive regular lifestyle counseling. Children with BMI > 95th centile require specialist pediatric care.
Service development	Children with comorbidity or severe obesity should receive their care in a multidisciplinary specialist service.

lifestyle, moderated caloric restriction targeted at inducing modest (5–10%) weight reduction associated with improvement of medical complications, a physical activity program emphasizing choice and reinforcing reduced sedentary behaviors, skills for managing high-risk situations, and skills for maintenance and relapse prevention.

### Conclusions

In the foregoing pages, we have described the problems associated with childhood obesity, providing strong evidence that adult morbidities may begin in early life. Perhaps because of the rapid evolution of these problems, public policy makers have not yet taken action to address existing and future repercussions. Obesity is now a major contributing factor to increasing rates of disability among adults (135). Health care costs of patients with a BMI greater than 35 are approximately 44% more than those of nonobese patients. Furthermore, it is well established that the health care costs of treating patients with T2DM, a common sequel of obesity, are substantially higher than treatment for patients without diabetes. This should provide incentive for the private and public sectors to: 1) mobilize all available resources to stem the tide of increasing body mass in children and adults, 2) classify obesity as a disease, paving the way for public funding and insurers' reimbursement for obesity treatment programs, and 3) spur further research to more effectively prevent and treat obesity. Precedents for successful public health campaigns include those designed to stem tobacco use, prevent the spread of HIV, and promote the use seat belts in motor vehicles and bicycle helmets in children. Professional societies (especially those dedicated to primary care and endocrinology), health care providers, and educators should assume leadership roles in achieving these goals (23). The WHO has formulated a plan to tackle obesity, and the IOTF has created a credentialing system for obesity specialists and treatment centers. In the United States, the Department of Health and Human Services recently convened an Obesity Summit to discuss the best means of addressing this critical public health problem. These are laudable milestones, which we hope will make inroads into ameliorating the crisis.

Measures to prevent childhood obesity are listed in Table 3, and basic lifestyle interventions are summarized in Table 4. An overall summary of this consensus development conference is presented in Table 5. These aspects must be em-

phasized as the safest means for primary care physicians to manage patients. The decision of when to intervene with pharmacotherapy or bariatric surgery must be made for children and adolescents on a case-by-case basis, according to the guidelines presented above. To date, although somewhat encouraging, only limited and short-term evidence is available to support the use of selected drugs or surgical procedures to alleviate morbid obesity in this population. Longer-term clinical trials with larger numbers of children and adolescents will be required before drug treatment or surgical intervention can be routinely employed.

### Acknowledgments

The following participants convened in Ein Bokek, Dead Sea, Israel, March 24–27, 2004, and contributed to this manuscript: R. Bahar-Einav, D. Bass-Rotenstein (Pittsburgh, PA); Z. Bistrizer (Zerifin, Israel); G. Brill, E. Leberman, Y. Limoni (Beersheva, Israel); S. Chalew (New Orleans, LA); J. Dahlgren (Gotheburg, Sweden); M. Golan, A. Hanukoglu, A. Zung (Rehovot, Israel); A. Golander, E. Gur, A. Kochli, Z. Laron, D. Levin, Y. Meirovitch, D. Modan-Mozes, N. Leventhal, Zohar Landau, E. Zuberly (Tel Aviv, Israel); H. Guttman, I. Koren, Y. Levy, D. Tiosano (Haifa, Israel); H. Hirsch, H. Landau, D. Zangen (Jerusalem, Israel); L. Karaviti (Houston, TX); A. Kurtev (Sofia, Bulgaria); M. Lampit (Zefat, Israel); I. Poraz (Petah Tikva, Israel); Y. Rakover (Afula, Israel); T. J. Rozenberg (Jerusalem, Israel); J. Popovic (Kansas City, MO); C. Silverstein, S. Ten (Brooklyn, NY); R. Weiss (New Haven, CT); and O. Yogev (Jerusalem, Israel).

The working group also acknowledges the contributions of: N. Dixit (Tucson, AZ); L. Edmunds (Bristol, UK); C. Maffei and L. Tatò (Verona, Italy); and A. Vargas (New Orleans, LA).

Received July 15, 2004. Accepted December 1, 2004.

Address all correspondence and requests for reprints to: Phyllis W. Speiser, M.D., Division of Pediatric Endocrinology, Schneider Children's Hospital, 269-01 76th Avenue, New Hyde Park, New York 11040. E-mail: pspeiser@lij.edu.

The work for the Consensus Conference was supported by Aventis, Ben Gurion University, Ferring Pharmaceuticals, Israel Society for Pediatric Endocrinology, Eli Lilly Co., Novo Nordisk, Pfizer, Roche, and Teva Pharmaceuticals.

### References

- Ogden CL, Flegal KM, Carroll MD, Johnson CL 2002 Prevalence and trends in overweight among U.S. children and adolescents, 1999–2000. *JAMA* 288: 1728–1732
- Cole TJ, Bellizzi MC, Flegal KM, Dietz WH 2000 Establishing a standard definition for child overweight and obesity worldwide: international survey. *BMJ* 320:1240–1243
- Lissau I, Overpeck MD, Ruan WJ, Due P, Holstein BE, Hediger ML 2004

- Body mass index and overweight in adolescents in 13 European countries, Israel, and the United States. *Arch Pediatr Adolesc Med* 158:27–33
4. **Lobstein T, Frelut ML** 2003 Prevalence of overweight among children in Europe. *Obes Rev* 4:195–200
  5. **Magarey AM, Daniels LA, Boulton TJ** 2001 Prevalence of overweight and obesity in Australian children and adolescents: reassessment of 1985 and 1995 data against new standard international definitions. *Med J Aust* 174:561–564
  6. **de Onis M, Blossner M** 2000 Prevalence and trends of overweight among preschool children in developing countries. *Am J Clin Nutr* 72:1032–1039
  7. **Guo SS, Wu W, Chumlea WC, Roche AF** 2002 Predicting overweight and obesity in adulthood from body mass index values in childhood and adolescence. *Am J Clin Nutr* 76:653–658
  8. 1998 Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the Evidence Report. National Institutes of Health. *Obes Res* 6(Suppl 2):515–2095
  9. **Lev-Ran A** 2001 Human obesity: an evolutionary approach to understanding our bulging waistline. *Diabetes Metab Res Rev* 17:347–362
  10. **O’Rahilly S, Farooqi IS, Yeo GS, Challis BG** 2003 Minireview: human obesity—lessons from monogenic disorders. *Endocrinology* 144:3757–3764
  11. **Clement K, Ferre P** 2003 Genetics and the pathophysiology of obesity. *Pediatr Res* 53:721–725
  12. **Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH** 1997 Predicting obesity in young adulthood from childhood and parental obesity. *N Engl J Med* 337:869–873
  13. **Freedman DS, Khan LK, Serdula MK, Dietz WH, Srinivasan SR, Berenson GS** 2004 Inter-relationships among childhood BMI, childhood height, and adult obesity: the Bogalusa Heart Study. *Int J Obes Relat Metab Disord* 28:10–16
  14. **Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL** 2002 Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. *Pediatrics* 109:45–60
  15. **Morrison JA, Sprecher DL, Barton BA, Waclawiw MA, Daniels SR** 1999 Overweight, fat patterning, and cardiovascular disease risk factors in black and white girls: the National Heart, Lung, and Blood Institute Growth and Health Study. *J Pediatr* 135:458–464
  16. **Reilly JJ** 2002 Assessment of childhood obesity: national reference data or international approach? *Obes Res* 10:838–840
  17. **Bellizzi MC, Dietz WH** 1999 Workshop on childhood obesity: summary of the discussion. *Am J Clin Nutr* 70:173S–175S
  18. **Sardinha LB, Going SB, Teixeira PJ, Lohman TG** 1999 Receiver operating characteristic analysis of body mass index, triceps skinfold thickness, and arm girth for obesity screening in children and adolescents. *Am J Clin Nutr* 70:1090–1095
  19. **Thompson DL, Thompson WR, Prestridge TJ, Bailey JG, Bean MH, Brown SP, McDaniel JB** 1991 Effects of hydration and dehydration on body composition analysis: a comparative study of bioelectric impedance analysis and hydrodensitometry. *J Sports Med Phys Fitness* 31:565–570
  20. **Stanforth PR, Jackson AS, Green JS, Gagnon J, Rankinen T, Despres JP, Bouchard C, Leon AS, Rao DC, Skinner JS, Wilmore JH** 2004 Generalized abdominal visceral fat prediction models for black and white adults aged 17–65 y: the HERITAGE Family Study. *Int J Obes Relat Metab Disord* 28:925–932
  21. **Bigaard J, Tjonneland A, Thomsen BL, Overvad K, Heitmann BL, Sorensen TIA** 2003 Waist circumference, BMI, smoking, and mortality in middle-aged men and women. *Obes Res* 11:895–903
  22. **Maffei C, Pietrobello A, Grezzani A, Provera S, Tato L** 2001 Waist circumference and cardiovascular risk factors in prepubertal children. *Obes Res* 9:179–187
  23. **Cuttler L, Whittaker JL, Kodish ED** 2003 Pediatric obesity policy: the danger of skepticism. *Arch Pediatr Adolesc Med* 157:722–724
  24. **Fernandez JR, Redden DT, Pietrobello A, Allison DB** 2004 Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. *J Pediatr* 145:439–444
  25. **McCarthy HD, Jarrett KV, Crawley HF** 2001 The development of waist circumference percentiles in British children aged 5.0–16.9 y. *Eur J Clin Nutr* 55:902–907
  26. **Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jebb SA, Perna F, Fontana S, Lechler RI, DePaoli AM, O’Rahilly S** 2002 Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. *J Clin Invest* 110:1093–1103
  27. **Krude H, Biebermann H, Gruters A** 2003 Mutations in the human proopiomelanocortin gene. *Ann NY Acad Sci* 994:233–239
  28. **Damcott CM, Feingold E, Moffett SP, Barmada MM, Marshall JA, Hamman RF, Ferrell RE** 2004 Genetic variation in uncoupling protein 3 is associated with dietary intake and body composition in females. *Metabolism* 53:458–464
  29. **Krude H, Biebermann H, Schnabel D, Tansek MZ, Theunissen P, Mullis PE, Gruters A** 2003 Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4–10. *J Clin Endocrinol Metab* 88:4633–4640
  30. **Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P** 2000 Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. *J Clin Invest* 106:253–262
  31. **Le Stunff C, Fallin D, Schork NJ, Bougneres P** 2000 The insulin gene VNTR is associated with fasting insulin levels and development of juvenile obesity. *Nat Genet* 26:444–446
  32. **Snyder EE, Walts B, Perusse L, Chagnon YC, Weisnagel SJ, Rankinen T, Bouchard C** 2004 The human obesity gene map: the 2003 update. *Obes Res* 12:369–439
  33. **Bouchard C** 1997 Genetic determinants of regional fat distribution. *Hum Reprod* 12(Suppl 1):1–5
  34. **Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, Schwartz MW, Basdevant A, Weigle DS** 2002 Elevated plasma ghrelin levels in Prader Willi syndrome. *Nat Med* 8:643–644
  35. **Grace C, Beales P, Summerbell C, Jebb SA, Wright A, Parker D, Kopelman P** 2003 Energy metabolism in Bardet-Biedl syndrome. *Int J Obes Relat Metab Disord* 27:1319–1324
  36. **Kim JC, Badano JL, Sibold S, Esmail MA, Hill J, Hoskins BE, Leitch CC, Venner K, Ansley SJ, Ross AJ, Leroux MR, Katsanis N, Beales PL** 2004 The Bardet-Biedl protein BBS4 targets cargo to the pericentriolar region and is required for microtubule anchoring and cell cycle progression. *Nat Genet* 36:462–470
  37. **Rosenbaum M, Gertner JM, Gidfarr N, Hirsch J, Leibel RL** 1992 Effects of systemic growth hormone (GH) administration on regional adipose tissue in children with non-GH-deficient short stature. *J Clin Endocrinol Metab* 75:151–156
  38. **Kokkoris P, Pi-Sunyer FX** 2003 Obesity and endocrine disease. *Endocrinol Metab Clin North Am* 32:895–914
  39. **Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG** 2000 Central nervous system control of food intake. *Nature* 404:661–671
  40. **Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, Savoye M, Rieger V, Taksali S, Barbetta G, Sherwin RS, Caprio S** 2002 Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. *N Engl J Med* 346:802–810
  41. **Lustig RH, Post SR, Srivannaboon K, Rose SR, Danish RK, Burghen GA, Xiong X, Wu S, Merchant TE** 2003 Risk factors for the development of obesity in children surviving brain tumors. *J Clin Endocrinol Metab* 88:611–616
  42. **Tiosano D, Eisentein I, Militianu D, Chrousos GP, Hochberg Z** 2003 11 $\beta$ -Hydroxysteroid dehydrogenase activity in hypothalamic obesity. *J Clin Endocrinol Metab* 88:379–384
  43. **Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger Jr JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S** 2004 Physical health monitoring of patients with schizophrenia. *Am J Psychiatry* 161:1334–1349
  44. 2004 Consensus development conference on antipsychotic drugs and obesity and diabetes. *Diabetes Care* 27:596–601
  45. **Perusse L, Bouchard C** 2000 Gene-diet interactions in obesity. *Am J Clin Nutr* 72:1285S–1290S
  46. **Zhang Q, Wang Y** 2004 Socioeconomic inequality of obesity in the United States: do gender, age, and ethnicity matter? *Soc Sci Med* 58:1171–1180
  47. American Obesity Association Fact Sheet: [http://www.obesity.org/subs/fastfacts/obesity\\_US.shtml](http://www.obesity.org/subs/fastfacts/obesity_US.shtml). World Wide Web. 2004. 6–2-2004.
  48. **Moore LL, Gao D, Bradlee ML, Cupples LA, Sundarajan-Ramamurti A, Proctor MH, Hood MY, Singer MR, Ellison RC** 2003 Does early physical activity predict body fat change throughout childhood? *Prev Med* 37:10–17
  49. **The Henry J. Kaiser Family Foundation** The role of media in childhood obesity: [http://www.kff.org/entmedia/upload/32431\\_1.pdf](http://www.kff.org/entmedia/upload/32431_1.pdf). World Wide Web. 2004. 6–2-2004.
  50. **Bowman SA, Gortmaker SL, Ebbeling CB, Pereira MA, Ludwig DS** 2004 Effects of fast-food consumption on energy intake and diet quality among children in a national household survey. *Pediatrics* 113:112–118
  51. **Bowman SA, Vinyard BT** 2004 Fast food consumption of U.S. adults: impact on energy and nutrient intakes and overweight status. *J Am Coll Nutr* 23:163–168
  52. **Heaney RP, Davies KM, Barger-Lux MJ** 2002 Calcium and weight: clinical studies. *J Am Coll Nutr* 21:152S–155S
  53. **Ludwig DS, Peterson KE, Gortmaker SL** 2001 Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis. *Lancet* 357:505–508
  54. **French SA, Harnack L, Jeffery RW** 2000 Fast food restaurant use among women in the Pound of Prevention study: dietary, behavioral and demographic correlates. *Int J Obes Relat Metab Disord* 24:1353–1359
  55. **Ebbeling CB, Sinclair KB, Pereira MA, Garcia-Lago E, Feldman HA, Ludwig DS** 2004 Compensation for energy intake from fast food among overweight and lean adolescents. *JAMA* 291:2828–2833
  56. **Grummer-Strawn LM, Mei Z** 2004 Does breastfeeding protect against pediatric overweight? Analysis of longitudinal data from the Centers for Disease Control and Prevention Pediatric Nutrition Surveillance System. *Pediatrics* 113:e81–e86

57. Victora CG, Barros F, Lima RC, Horta BL, Wells J 2003 Anthropometry and body composition of 18 year old men according to duration of breast feeding: birth cohort study from Brazil. *BMJ* 327:901
58. Zadik Z, Borondukov E, Zung A, Reifen R 2003 Adult height and weight of breast-fed and bottle-fed Israeli infants. *J Pediatr Gastroenterol Nutr* 37:462–467
59. Yanovski SZ, Nelson JE, Dubbert BK, Spitzer RL 1993 Association of binge eating disorder and psychiatric comorbidity in obese subjects. *Am J Psychiatry* 150:1472–1479
60. Britz B, Siegfried W, Ziegler A, Lamertz C, Herpertz-Dahlmann BM, Remschmidt H, Wittchen HU, Hebebrand J 2000 Rates of psychiatric disorders in a clinical study group of adolescents with extreme obesity and in obese adolescents ascertained via a population based study. *Int J Obes Relat Metab Disord* 24:1707–1714
61. Zametkin AJ, Zoon CK, Klein HW, Munson S 2004 Psychiatric aspects of child and adolescent obesity: a review of the past 10 years. *J Am Acad Child Adolesc Psychiatry* 43:134–150
62. Epstein LH, Roemmich JN, Raynor HA 2001 Behavioral therapy in the treatment of pediatric obesity. *Pediatr Clin North Am* 48:981–993
63. Schwimmer JB, Burwinkle TM, Varni JW 2003 Health-related quality of life of severely obese children and adolescents. *JAMA* 289:1813–1819
64. Strauss RS, Pollack HA 2003 Social marginalization of overweight children. *Arch Pediatr Adolesc Med* 157:746–752
65. Falkner NH, Neumark-Sztainer D, Story M, Jeffery RW, Beuhring T, Resnick MD 2001 Social, educational, and psychological correlates of weight status in adolescents. *Obes Res* 9:32–42
66. Gahagan S, Silverstein J, the Committee on Native American Child Health and Section on Endocrinology 2003 Prevention and treatment of type 2 diabetes mellitus in children, with special emphasis on American Indian and Alaska Native children. *Pediatrics* 112:e328
67. Gungor N, Saad R, Janosky J, Arslanian S 2004 Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. *J Pediatr* 144:47–55
68. 2002 Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 106:3143–3421
69. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lermmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P 2003 Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 26:3160–3167
70. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH 2003 Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. *Arch Pediatr Adolesc Med* 157:821–827
71. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S 2004 Obesity and the metabolic syndrome in children and adolescents. *N Engl J Med* 350:2362–2374
72. Alberti KG, Zimmet PZ 1998 Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 15:539–553
73. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW 2003 American College of Endocrinology position statement on the insulin resistance syndrome. *Endocr Pract* 9:237–252
74. Wabitsch M, Hauner H, Heinze E, Bockmann A, Benz R, Mayer H, Teller W 1995 Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. *J Clin Endocrinol Metab* 80:3469–3475
75. Horton R, Tait JF 1966 Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. *J Clin Invest* 45:301–313
76. Apter D, Butzow T, Laughlin GA, Yen SS 1995 Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. *J Clin Endocrinol Metab* 80:2966–2973
77. Urbina EM, Gidding SS, Bao W, Elkasabany A, Berenson GS 1999 Association of fasting blood sugar level, insulin level, and obesity with left ventricular mass in healthy children and adolescents: The Bogalusa Heart Study. *Am Heart J* 138:122–127
78. Freedman DS, Dietz WH, Tang R, Mensah GA, Bond MG, Urbina EM, Srinivasan S, Berenson GS 2004 The relation of obesity throughout life to carotid intima-media thickness in adulthood: the Bogalusa Heart Study. *Int J Obes Relat Metab Disord* 28:159–166
79. Lurbe E, Alvarez V, Redon J 2001 Obesity, body fat distribution, and ambulatory blood pressure in children and adolescents. *J Clin Hypertens (Greenwich)* 3:362–367
80. Schachter LM, Peat JK, Salome CM 2003 Asthma and atopy in overweight children. *Thorax* 58:1031–1035
81. Gupta NK, Mueller WH, Chan W, Meininger JC 2002 Is obesity associated with poor sleep quality in adolescents? *Am J Human Biol* 14:762–768
82. Young T, Peppard PE, Gottlieb DJ 2002 Epidemiology of obstructive sleep apnea: a population health perspective. *Am J Respir Crit Care Med* 165:1217–1239
83. Young T, Skatrud J, Peppard PE 2004 Risk factors for obstructive sleep apnea in adults. *JAMA* 291:2013–2016
84. Bray GA 2003 Risks of obesity. *Endocrinol Metab Clin North Am* 32:787–804, viii
85. Boland LL, Folsom AR, Rosamond WD 2002 Hyperinsulinemia, dyslipidemia, and obesity as risk factors for hospitalized gallbladder disease. A prospective study. *Ann Epidemiol* 12:131–140
86. Yanovski JA 2001 Pediatric obesity. *Rev Endocr Metab Disord* 2:371–383
87. Jabbour SA 2003 Cutaneous manifestations of endocrine disorders: a guide for dermatologists. *Am J Clin Dermatol* 4:315–331
88. Giuseffi V, Wall M, Siegel PZ, Rojas PB 1991 Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case-control study. *Neurology* 41:239–244
89. Bhargava SK, Sachdev HS, Fall CH, Osmond C, Lakshmy R, Barker DJ, Biswas SK, Ramji S, Prabhakaran D, Reddy KS 2004 Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. *N Engl J Med* 350:865–875
90. Hediger ML, Overpeck MD, McGlynn A, Kuczmarski RJ, Maurer KR, Davis WW 1999 Growth and fatness at three to six years of age of children born small- or large-for-gestational age. *Pediatrics* 104:e33
91. Ravelli GP, Stein ZA, Susser MW 1976 Obesity in young men after famine exposure *in utero* and early infancy. *N Engl J Med* 295:349–353
92. Barker DJ, Eriksson JG, Forsen T, Osmond C 2002 Fetal origins of adult disease: strength of effects and biological basis. *Int J Epidemiol* 31:1235–1239
93. Wang LY, Yang Q, Lowry R, Wechsler H 2003 Economic analysis of a school-based obesity prevention program. *Obes Res* 11:1313–1324
94. Kubik MY, Lytle LA, Hannan PJ, Perry CL, Story M 2003 The association of the school food environment with dietary behaviors of young adolescents. *Am J Public Health* 93:1168–1173
95. Lackey CJ, Kolasa KM 2004 Healthy eating: defining the nutrient quality of foods. *Nutr Today* 39:26–29
96. Gordon-Larsen P, McMurray RG, Popkin BM 1999 Adolescent physical activity and inactivity vary by ethnicity: The National Longitudinal Study of Adolescent Health. *J Pediatr* 135:301–306
97. McTigue KM, Harris R, Hemphill B, Lux L, Sutton S, Buntun AJ, Lohr KN 2003 Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 139:933–949
98. Campbell KJ, Waters E, O'Meara S, Kelly S, Summerbell CD 2004 Interventions for preventing obesity in children (Cochrane review). Chichester, UK: John Wiley and Sons, Ltd.
99. Karelis AD, St. Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET 2004 Metabolic and body composition factors in subgroups of obesity: what do we know? *J Clin Endocrinol Metab* 89:2569–2575
100. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 346:393–403
101. Epstein LH, Valoski A, Wing RR, McCurley J 1990 Ten-year follow-up of behavioral, family-based treatment for obese children. *JAMA* 264:2519–2523
102. Golan M, Weizman A 2001 Familial approach to the treatment of childhood obesity: conceptual model. *J Nutr Educ Behav* 33:102–107
103. Summerbell CD, Ashton V, Campbell KJ, Edmunds L, Kelly S, Waters E 2003 Interventions for treating obesity in children. *Cochrane Database Syst Rev* CD001872
104. Golan M, Crow S 2004 Targeting parents exclusively in the treatment of childhood obesity: long-term results. *Obes Res* 12:357–361
105. Epstein LH, Myers MD, Raynor HA, Saelens BE 1998 Treatment of pediatric obesity. *Pediatrics* 101:554–570
106. Hirsch J, Hudgins LC, Leibel RL, Rosenbaum M 1998 Diet composition and energy balance in humans. *Am J Clin Nutr* 67:551S–555S
107. St. Jeor ST, Howard BV, Previtt TE, Bovee V, Bazzarre T, Eckel RH 2001 Dietary protein and weight reduction: a statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. *Circulation* 104:1869–1874
108. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary PO, Rader DJ, Edman JS, Klein S 2003 A randomized trial of a low-carbohydrate diet for obesity. *N Engl J Med* 348:2082–2090
109. Sondike SB, Copperman N, Jacobson MS 2003 Effects of a low-carbohydrate diet on weight loss and cardiovascular risk factor in overweight adolescents. *J Pediatr* 142:253–258
110. Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams T, Williams M, Gracely EJ, Stern L 2003 A low-carbohydrate as compared with a low-fat diet in severe obesity. *N Engl J Med* 348:2074–2081
111. Giammattei J, Blix G, Marshak HH, Wollitzer AO, Pettitt DJ 2003 Television watching and soft drink consumption: associations with obesity in 11- to 13-year-old schoolchildren. *Arch Pediatr Adolesc Med* 157:882–886

112. **Ebbeling CB, Leidig MM, Sinclair KB, Hangen JP, Ludwig DS** 2003 A reduced-glycemic load diet in the treatment of adolescent obesity. *Arch Pediatr Adolesc Med* 157:773–779
113. **James J, Thomas P, Cavan D, Kerr D** 2004 Preventing childhood obesity by reducing consumption of carbonated drinks: cluster randomised controlled trial. *BMJ* 328:1237
114. **Slavin J** 2003 Why whole grains are protective: biological mechanisms. *Proc Nutr Soc* 62:129–134
115. **O'Keefe Jr JH, Cordain L** 2004 Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer. *Mayo Clin Proc* 79:101–108
116. **Grundy SM, Blackburn G, Higgins M, Lauer R, Perri MG, Ryan D** 1999 Physical activity in the prevention and treatment of obesity and its comorbidities: evidence report of independent panel to assess the role of physical activity in the treatment of obesity and its comorbidities. *Med Sci Sports Exerc* 31:1493–1500
117. **Goodpaster BH, Katsiaras A, Kelley DE** 2003 Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. *Diabetes* 52:2191–2197
118. **Ferguson MA, Gutin B, Le NA, Karp W, Litaker M, Humphries M, Okuyama T, Riggs S, Owens S** 1999 Effects of exercise training and its cessation on components of the insulin resistance syndrome in obese children. *Int J Obes Relat Metab Disord* 23:889–895
119. **Watts K, Beye P, Siafarikas A, Davis EA, Jones TW, O'Driscoll G, Green DJ** 2004 Exercise training normalizes vascular dysfunction and improves central adiposity in obese adolescents. *J Am Coll Cardiol* 43:1823–1827
120. **Pinelli L, Elerdini N, Faith MS, Agnello D, Ambruzzi A, De Simone M, Leggeri G, Livieri C, Monetti N, Peverelli P, Salvatoni A, Seminara S, Uasone R, Pietrobelli A** 1999 Childhood obesity: results of a multicenter study of obesity treatment in Italy. *J Pediatr Endocrinol Metab* 12(Suppl 3):795–799
121. **Molnar D, Torok K, Erhardt E, Jeges S** 2000 Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. *Int J Obes Relat Metab Disord* 24:1573–1578
122. **Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL** 2003 Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. *JAMA* 289:1805–1812
123. **McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA** 2002 Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. *Obes Res* 10:642–650
124. **Freemark M, Bursey D** 2001 The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. *Pediatrics* 107:E55
125. **Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S** 2001 Beneficial effects of metformin in normoglycemic morbidly obese adolescents. *Metabolism* 50:1457–1461
126. **Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE, Rai SN, Lensing SY, Wu S, Xiong X** 2003 Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. *J Clin Endocrinol Metab* 88:2586–2592
127. **Inge TH, Garcia V, Daniels S, Langford L, Kirk S, Roehrig H, Amin R, Zeller M, Higa K** 2004 A multidisciplinary approach to the adolescent bariatric surgical patient. *J Pediatr Surg* 39:442–447
128. **Sugerman HJ, Sugerman EL, DeMaria EJ, Kellum JM, Kennedy C, Mowery Y, Wolfe LG** 2003 Bariatric surgery for severely obese adolescents. *J Gastrointest Surg* 7:102–107
129. **Sjostrom CD, Lissner L, Wedel H, Sjostrom L** 1999 Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. *Obes Res* 7:477–484
130. **Garcia VF, Langford L, Inge TH** 2003 Application of laparoscopy for bariatric surgery in adolescents. *Curr Opin Pediatr* 15:248–255
131. **Korner J, Aronne LJ** 2004 Pharmacological approaches to weight reduction: therapeutic targets. *J Clin Endocrinol Metab* 89:2616–2621
132. American Heart Association. Obesity, Overweight in Children: <http://www.americanheart.org/presenter.jhtml?identifier=4670>. World Wide Web. 2004. 6–3-2004.
133. **Eriksson JG, Forsen T, Tuomilehto J, Osmond C, Barker DJ** 2003 Early adiposity rebound in childhood and risk of type 2 diabetes in adult life. *Diabetologia* 46:190–194
134. **Barlow SE, Dietz WH** 1998 Obesity evaluation and treatment: Expert Committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. *Pediatrics* 102:e29
135. **Visscher TL, Seidell JC** 2001 The public health impact of obesity. *Annu Rev Public Health* 22:355–375

JCEM is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.